Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (151-160 of 289) with videos related to

Pageof 29
Sort By:
European Urology Oncology|November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate CancerFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
European Urology Oncology|February 9, 2025
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi StudyLaurence Albiges, Marine Gross-Goupil, Philippe Barthélémy, et al.
Scientific Reports|February 23, 2021
First prospective data on breast cancer patients from the multicentre italian bone metastasis databaseAlberto Bongiovanni, Flavia Foca, Manuela Fantini, et al.
Clinical Genitourinary Cancer|March 2, 2015
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral CenterAndrea Necchi, Elena Farè, Salvatore Lo Vullo, et al.
Investigational New Drugs|February 14, 2016
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancerAndrea Necchi, Salvatore Lo Vullo, Luigi Mariani, et al.
Clinical and Translational Medicine|June 29, 2021
Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patientsDarawan Rinchai, Elena Verzoni, Veronica Huber, et al.
BJU International|May 24, 2011
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesCamillo Porta, Giuseppe Procopio, Giacomo Cartenì, et al.
Oncology|February 17, 2017
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted AgentsPaolo Grassi, Ludovic Doucet, Palma Giglione, et al.
La Radiologia Medica|March 18, 2022
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Antonio Orlacchio, Carlo Guastoni, Giordano Domenico Beretta, et al.
Immunotherapy|November 17, 2021
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, et al.
Pageof 29

Showing results (151-160 of 289) with videos related to

Sort By:
Pageof 29
European Urology Oncology|November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate CancerFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
European Urology Oncology|February 9, 2025
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi StudyLaurence Albiges, Marine Gross-Goupil, Philippe Barthélémy, et al.
Scientific Reports|February 23, 2021
First prospective data on breast cancer patients from the multicentre italian bone metastasis databaseAlberto Bongiovanni, Flavia Foca, Manuela Fantini, et al.
Clinical Genitourinary Cancer|March 2, 2015
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral CenterAndrea Necchi, Elena Farè, Salvatore Lo Vullo, et al.
Investigational New Drugs|February 14, 2016
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancerAndrea Necchi, Salvatore Lo Vullo, Luigi Mariani, et al.
Clinical and Translational Medicine|June 29, 2021
Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patientsDarawan Rinchai, Elena Verzoni, Veronica Huber, et al.
BJU International|May 24, 2011
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesCamillo Porta, Giuseppe Procopio, Giacomo Cartenì, et al.
Oncology|February 17, 2017
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted AgentsPaolo Grassi, Ludovic Doucet, Palma Giglione, et al.
La Radiologia Medica|March 18, 2022
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Antonio Orlacchio, Carlo Guastoni, Giordano Domenico Beretta, et al.
Immunotherapy|November 17, 2021
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, et al.
Pageof 29